RxSIGHT, INC. RXST 深 滬
已收盤 08-29 16:00:00 美东时间
9.04
-0.110
-1.20%
華盛通- 最 高9.25
- 今 開9.14
- 成交量 115.26万股
- 最 低 8.9541
- 昨 收 9.15
- 總市值 3.70亿
- 52周最高 57.53
- 市盈率 靜 --
- 換手率 2.82%
- 52周最低 6.32
- 委 比 -80.67%
- 總股本 4091.60万
- 歷史最高 66.54
- 量 比 0.91
- 振 幅 3.23%
- 歷史最低 6.32
- 每 手 1
- 風險率 15.82%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多RxSight, Inc. (RXST) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES, Aug. 14, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST) have opp...
08-15 00:00
RxSight, Inc. to Present at the Wells Fargo Healthcare Conference
RxSight, Inc., an ophthalmic medical device company specializing in customized vision solutions following cataract surgery, announced its participation in the upcoming Wells Fargo Healthcare Conference in Boston. The presentation by RxSight’s management is scheduled for Thursday, September 4, 2025, at 7:15 a.m. Pacific Time / 10:15 a.m. Eastern Time. A live and archived webcast will be available at https://www.globenewswire.com/Tracker?data=M2_wL...
08-14 20:05
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
Needham Maintains Buy on RxSight, Lowers Price Target to $11
Needham analyst David Saxon maintains RxSight (NASDAQ:RXST) with a Buy and lowers the price target from $22 to $11.
08-08 19:20
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Vertical Aerospace reports 1H results
Vertical Aerospace press release (NYSE:EVTL): 1H Net profit of £250M Outlook: Maintained industry-leading capital efficiency and after July’s successful fundraise of gross proceeds of $69 million (£50...
08-05 19:51
RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors
RxSight, Inc. announced the appointment of Raymond W. Cohen to its Board of Directors. Cohen, a seasoned medical technology executive with over four decades of experience, brings significant expertise in scaling successful companies. He co-founded and led Axonics, Inc., which achieved exceptional growth and was acquired by Boston Scientific for $3.7 billion. Cohen also recently led the sale of SoniVie, Ltd., to Boston Scientific for $600 million....
08-04 12:05
AES gives mixed Q2 results, reaffirms outlokk
AES press release (NYSE:AES): Q2 Non-GAAP EPS of $0.51 beats by $0.11. Revenue of $2.86B (-2.7% Y/Y) misses by $150M. Net Loss of $150 million, compared to Net Income of $153 million in Q2 2024 Net Lo...
08-01 12:34
Berger Montague PC Investigates Securities Claims Against RxSight, Inc. (NASDAQ: RXST)
PHILADELPHIA, July 25, 2025 /PRNewswire/ -- Berger Montague PC, a national securities litigation law firm announces it is investigating potential securities fraud claims involving RxSight, I...
07-26 02:26
RxSight, Inc. to Report Second Quarter 2025 Financial Results on August 7, 2025
<p>RxSight, Inc., an ophthalmic medical device company, will report 2Q25 financial results after market close on August 7, 2025. Management will discuss results during a conference call at 1:30 p.m. PT / 4:30 p.m. ET. The call can be accessed via phone (800)—715—9871 or (646)—307—1963, using conference code 633359, or via the company’s investor relations website. RxSight offers the Light Adjustable Lens system, the only intraocular lens technolog...
07-24 20:05
